Arcturus Therapeutics Holdings Inc (ARCT)vsModerna Inc (MRNA)
ARCT
Arcturus Therapeutics Holdings Inc
$12.15
+0.66%
HEALTHCARE · Cap: $293.89M
MRNA
Moderna Inc
$222.76
+4.01%
HEALTHCARE · Cap: $85.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 7486% more annual revenue ($2.23B vs $29.37M). ARCT leads profitability with a 0.0% profit margin vs -141.4%. ARCT earns a higher WallStSmart Score of 24/100 (F).
ARCT
Avoid24
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.9%
Fair Value
$17.59
Current Price
$12.15
$5.44 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$222.76
$88.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 13.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARCT
The strongest argument for ARCT centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ARCT
The primary concerns for ARCT are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARCT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
ARCT carries more volatility with a beta of 2.48 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ARCT generates stronger free cash flow (-20M), providing more financial flexibility.
Bottom Line
ARCT scores higher overall (24/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arcturus Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases. The company is headquartered in San Diego, California.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?